中国实用外科杂志 ›› 2009, Vol. 29 ›› Issue (12): 989-992.

• 专题笔谈 • 上一篇    下一篇

糖皮质激素在感染性休克治疗中的作用及评价

季宪飞李春盛   

  1. 首都医科大学附属朝阳医院,北京100020
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2009-12-18 发布日期:2009-12-18

  • Received:1900-01-01 Revised:1900-01-01 Online:2009-12-18 Published:2009-12-18

摘要:

糖皮质激素在感染性休克病人中的应用一直存在争议。在20世纪70~80年代,大剂量、短疗程的糖皮质激素成为治疗感染性休克的标准疗法。 而20世纪80年代后期两项大型临床试验发现糖皮质激素并不能降低感染性休克病人的病死率,甚至有害,糖皮质激素作为严重感染及感染性休克治疗的临床应用明显减少。20世纪90年代后期和21世纪初期的研究发现小剂量糖皮质激素、长疗程使用可提高感染性休克病人的存活率,但最近的CORTICUS研究显示小剂量糖皮质激素并没降低感染性休克病人的28d病死率,却增加二重感染。尽管关于糖皮质激素在感染性休克中应用的安全性和有效性研究进行了半个世纪,至今仍存在争议。

关键词: 糖皮质激素, 感染性休克, 氢化可的松

Abstract:

Role of glucocorticoids in the treatment of septic shock JI Xian-fei,LI Chun-sheng. Department of Emergency, Beijing Chaoyang Hospital Affiliated to Capital University of Medical Science, Beijing 100020, China Corresponding author: LI Chun-sheng,E-mail:lcscyyy@sohu.com Abstract The use of glucocorticoids in septic shock patients has been controversial for decades. High-dose glucocorticoids were standard therapy in the 1970s and 1980s. During the late 1980s, the consensus was that glucocorticoids should not be used in sepsis and septic shock after two studies with broad scale had not shown an improved survival, even had been harmful for patients treated with steroids. Studies in the late 1990s and early 2000s demonstrated the lower doses of glucocorticoids for longer periods would reverse shock and even improve survival. However, the recent CORTICUS study did demonstrate the lower doses of glucocorticoids increased incidence of superinfection including new sepsis or septic shock, but did not decrease 28-day mortality rate. It is noteworthy that the efficacy and safety of glucocorticoids in sepsis have been investigated in randomized controlled trials for half a century, and still, the treatment remains controversial.

Key words: glucocorticoids, septic shock, hydrocortisone